News | May 08, 2024
AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
The Product is expected to be the first generic approval on the market
Subscribe To Our Newsletter & Stay Updated
